How Hyperbaric Oxygen Therapy May Support Bladder Healing After Pelvic Radiation
Radiation therapy is an essential component of care for many pelvic cancers, including prostate, bladder, cervical, endometrial, rectal, and other malignancies. While modern treatment planning limits exposure to surrounding organs, the bladder may still receive enough radiation to produce tissue injury.
Radiation cystitis can cause urinary frequency, urgency, pain, burning, incontinence, and blood in the urine. In more severe cases, bleeding may become persistent, produce clots, obstruct urinary drainage, require transfusion, or lead to repeated hospitalizations and invasive procedures.
Hyperbaric oxygen therapy, commonly abbreviated as HBOT, may be used to treat selected patients with chronic radiation injury of the bladder. Its role is different from bladder irrigation, cauterization, embolization, or other interventions intended to stop active bleeding immediately. HBOT is intended to improve the underlying health of radiation-damaged tissue by increasing oxygen delivery and supporting vascular repair.
In the United States, radiation cystitis is generally treated within the recognized HBOT indication of delayed radiation injury or soft tissue radionecrosis. Medicare identifies soft tissue radionecrosis as a covered condition when HBOT is used as an adjunct to conventional treatment. (Centers for Medicare & Medicaid Services)
Acute and Chronic Radiation Cystitis Are Different
Urinary symptoms can develop during radiation treatment or appear months to years later. These presentations reflect different patterns of tissue injury.
Acute radiation cystitis occurs during or shortly after pelvic radiation. It is primarily an inflammatory response involving the bladder lining. Patients may experience urinary frequency, urgency, discomfort, or burning with urination. Symptoms often improve after radiation is completed, although infection and other causes must still be considered.
Chronic radiation cystitis is a delayed injury that may not become apparent until months or years after treatment. Radiation can progressively damage small blood vessels supplying the bladder wall. This process, sometimes described as obliterative endarteritis, leads to tissue hypoxia, reduced capillary density, fibrosis, mucosal atrophy, and fragile abnormal vessels that bleed easily. (eviQ)
Late radiation injury may produce:
- Visible or microscopic hematuria
- Recurrent bleeding or passage of clots
- Urinary urgency and frequency
- Dysuria or bladder pain
- Reduced bladder capacity
- Urinary incontinence
- Difficulty emptying the bladder
- Recurrent catheterization or hospitalization
The term hemorrhagic radiation cystitis is often used when bleeding is the dominant symptom. Not every patient with chronic radiation cystitis develops severe hematuria. Some experience persistent urgency, frequency, pain, or impaired bladder function without major bleeding.
Why Radiation-Damaged Bladder Tissue Does Not Heal Normally
Radiation injury can continue to evolve long after cancer treatment has ended. The initial exposure damages cellular DNA, vascular endothelium, and connective tissue. Over time, progressive narrowing and loss of small blood vessels reduce the tissue’s ability to deliver oxygen and nutrients.
The bladder wall may become chronically hypoxic and fibrotic. Normal repair is limited because the tissue lacks the vascular supply needed to support cellular metabolism, collagen remodeling, and mucosal regeneration.
New vessels that form spontaneously within irradiated tissue may be thin, irregular, and fragile. These telangiectatic vessels can rupture as the bladder fills and empties, causing recurrent hematuria.
Radiation injury can also affect bladder compliance. Fibrosis may make the bladder less elastic, producing urgency, frequent urination, pain during filling, and reduced functional capacity. Severe injury can occasionally contribute to ulceration, necrosis, fistula formation, or obstruction.
This is why simply cauterizing visible bleeding vessels may not provide lasting control. Fulguration can stop a specific bleeding point, but it does not necessarily correct the diffuse hypoxia and vascular injury affecting the surrounding bladder wall.
How HBOT May Help Radiation Cystitis
During HBOT, the patient breathes oxygen while exposed to increased atmospheric pressure inside a medical hyperbaric chamber. The elevated pressure increases arterial oxygen tension and substantially raises the amount of oxygen dissolved directly in plasma.
This oxygen-rich plasma can reach functioning vessels at the margins of irradiated tissue and establish a strong diffusion gradient into hypoxic areas. Repeated treatments are intended to create more than temporary hyperoxygenation.
Potentially relevant effects include:
- Increased oxygen delivery to hypoxic bladder tissue
- Stimulation of angiogenic signaling
- Formation and maturation of new capillary networks
- Support for fibroblast function and collagen remodeling
- Improved epithelial and mucosal repair
- Modulation of chronic inflammation
- Improved resistance of repaired tissue to recurrent injury
HBOT does not simply seal an actively bleeding vessel. The clinical objective is to improve the vascularity and biologic condition of the bladder wall so that the tissue becomes more capable of maintaining itself after the treatment course ends.
This distinction also explains why benefits may develop gradually. Some patients notice reduced bleeding during treatment, while others improve over the weeks or months that follow as vascular and tissue remodeling continue.
Hematuria After Radiation Still Requires a Urologic Evaluation
A history of pelvic radiation does not establish that every episode of hematuria is caused by radiation cystitis.
Blood in the urine may also result from:
- Recurrent or new urinary tract malignancy
- Urinary tract infection
- Kidney or bladder stones
- Prostatic bleeding
- Anticoagulant or antiplatelet therapy
- Renal disease
- Trauma or recent instrumentation
- Other inflammatory bladder conditions
The evaluation should establish that radiation injury is the likely cause and identify any immediate threat from bleeding or obstruction.
Depending on the presentation, the workup may include urinalysis, urine culture, blood counts, renal function testing, coagulation assessment, urine cytology, upper urinary tract imaging, and cystoscopy. Cystoscopic evaluation helps identify characteristic radiation changes, locate active bleeding, remove clots, and exclude bladder tumors or other pathology. (PubMed Central (PMC))
Biopsy may be considered when a suspicious lesion is present, but it should be approached carefully because irradiated bladder tissue can heal poorly. The decision belongs with the treating urologist and should reflect the risk of malignancy and the appearance of the lesion.
Severe Bleeding Must Be Stabilized Before or Alongside HBOT
HBOT is not a substitute for emergency management of significant blood loss, clot retention, or urinary obstruction.
A patient with heavy hematuria may require:
- Placement of a large-bore urinary catheter
- Manual clot evacuation
- Continuous bladder irrigation
- Intravenous fluids
- Correction of a clinically significant coagulopathy
- Blood transfusion
- Cystoscopic clot evacuation
- Fulguration or coagulation of bleeding sites
- Hospital admission and close monitoring
If bleeding remains uncontrolled, additional options may include intravesical agents, selective arterial embolization, urinary diversion, or surgery. The choice depends on bleeding severity, bladder condition, kidney function, previous treatments, and the patient’s overall medical status. (PubMed Central (PMC))
HBOT may be introduced once the patient is sufficiently stable to undergo daily chamber treatments. It can sometimes begin while other supportive measures continue, but it should not delay urgent clot removal, stabilization, or evaluation for recurrent cancer.
The Canadian Urological Association best practice report recommends considering HBOT relatively early after cystoscopy and fulguration have failed, rather than reserving it only for patients who have undergone multiple destructive or highly invasive therapies. (PubMed Central (PMC))
Which Patients May Be Considered for HBOT?
HBOT may be appropriate for patients with confirmed or strongly suspected delayed radiation injury of the bladder who continue to experience clinically meaningful symptoms.
Potential candidates include patients with:
- Persistent or recurrent radiation-related hematuria
- Bleeding that returns after cystoscopic treatment
- Chronic urinary urgency, frequency, or dysuria associated with radiation injury
- Transfusion-dependent or hospitalization-producing hemorrhagic cystitis
- Diffuse cystoscopic radiation changes that are difficult to treat focally
- A desire to preserve the bladder and avoid more invasive procedures
- Combined pelvic soft tissue radiation injury affecting nearby structures
The decision should consider the severity of symptoms, the degree of bladder damage, prior interventions, cancer status, medical comorbidities, and the patient’s ability to complete a daily treatment schedule.
Earlier referral may be beneficial. Retrospective studies have reported better responses when HBOT begins relatively soon after the onset of radiation-related hematuria, although the available data do not establish one universal referral deadline. The practical point is that patients do not necessarily need to exhaust every invasive option before receiving a hyperbaric evaluation.
HBOT is less likely to correct symptoms caused primarily by a fixed anatomic problem, such as severe urethral obstruction, a large fistula, extensive bladder contraction, an untreated tumor, or another condition requiring surgery.
What an HBOT Course for Radiation Cystitis May Involve
A treatment course is prescribed by a hyperbaric physician after reviewing the urologic evaluation, radiation history, current symptoms, medical risks, and previous treatments.
Protocols commonly involve treatment five days per week for several weeks. Treatment is often delivered at approximately 2.0 to 2.5 atmospheres absolute, with around 80 to 90 minutes of oxygen breathing at treatment pressure. Many patients receive 30 to 40 sessions, although additional treatments may be considered based on clinical response and treatment tolerance.
The RICH-ART randomized trial used 30 to 40 treatments with 100 percent oxygen at 240 to 250 kPa, approximately 2.4 to 2.5 ATA, for 80 to 90 minutes per session. (ScienceDirect)
A typical visit includes:
- Review of current symptoms and interval medical changes.
- Assessment of ear-pressure equalization and treatment readiness.
- Removal of prohibited items under hyperbaric fire-safety protocols.
- Gradual chamber compression.
- Oxygen breathing at the prescribed pressure.
- Air breaks when included in the protocol.
- Controlled decompression and post-treatment assessment.
Patients may be treated in either a monoplace or multiplace chamber. The clinical oxygen dose and safety of treatment are more important than the chamber configuration.
How Response to HBOT Is Measured
Visible hematuria is an important outcome, but it should not be the only measure of treatment success.
Radiation cystitis can affect several areas of urinary function and quality of life. Clinical monitoring may include:
- Frequency and severity of hematuria
- Number of clot-retention episodes
- Need for transfusion
- Emergency visits or hospitalizations
- Need for cystoscopy or fulguration
- Urinary frequency and urgency
- Dysuria and pelvic pain
- Incontinence
- Nighttime urination
- Patient-reported quality of life
A patient may experience meaningful improvement even when occasional mild hematuria persists. Conversely, cessation of visible bleeding does not necessarily mean that urgency, pain, or bladder-capacity limitations have resolved.
Standardized patient-reported instruments can help capture changes that are not reflected by laboratory values or cystoscopic findings alone. The RICH-ART study used the urinary domain of the Expanded Prostate Cancer Index Composite to evaluate urinary symptoms and the degree to which they affected daily life. (University of Michigan Medical School)
What the Clinical Evidence Shows
The evidence for HBOT in radiation cystitis includes case series, cohort studies, systematic reviews, and a multicenter randomized controlled trial.
A 2024 systematic review and meta-analysis reported improvement in symptoms among approximately 90 percent of included patients, with complete remission of hematuria in a pooled 55 percent. The studies varied in patient selection, severity, treatment protocols, and outcome definitions, so these figures should not be interpreted as a guaranteed individual response. (PubMed Central (PMC))
The RICH-ART randomized phase 2 to 3 trial found that HBOT improved patient-reported urinary symptoms compared with standard care in patients with chronic radiation cystitis. The trial evaluated a broader range of urinary problems rather than focusing only on visible bleeding. (ScienceDirect)
A 2025 five-year follow-up reported that benefits were sustained among patients who responded initially. Of 70 patients included in the long-term analysis, 68.6 percent met the study’s responder definition after HBOT. Their improvements remained clinically meaningful at five years. Nine patients received a second HBOT course because symptoms recurred. (PubMed Central (PMC))
These findings provide stronger evidence for durable symptom improvement, but important limitations remain. Not every patient responds, study populations may not represent the most severe cases of life-threatening hemorrhage, and the optimal pressure, number of sessions, and timing of treatment have not been established for every presentation.
HBOT should therefore be presented as a tissue-restorative treatment with meaningful evidence, not as a guaranteed cure or immediate method of hemostasis.
Risks and Contraindications of HBOT
HBOT is generally well tolerated when delivered in a medically supervised facility, but treatment has recognized risks.
Potential adverse effects include:
- Middle-ear or sinus barotrauma
- Temporary myopic vision changes
- Claustrophobia or confinement anxiety
- Pulmonary oxygen effects
- Blood glucose changes in patients with diabetes
- Rare oxygen-induced seizure
An untreated pneumothorax is generally considered an absolute contraindication. Patients with pulmonary disease, difficulty equalizing ear pressure, uncontrolled fever, unstable heart failure, seizure risk, or implanted medical devices require individualized assessment.
Cancer history also requires thoughtful evaluation. HBOT is used to treat complications of previous radiation, not active malignancy itself. A patient should have an appropriate oncologic and urologic assessment to determine whether recurrent or persistent cancer may be contributing to the symptoms.
Practical Considerations for Patients
A full course of HBOT requires a significant time commitment. Patients commonly attend treatment five days per week for six to eight weeks, in addition to urology, oncology, primary care, or other appointments.
Transportation, work obligations, urinary urgency, catheter care, mobility limitations, and fatigue can affect attendance. Some patients are also understandably anxious about entering a chamber after already enduring cancer treatment and repeated urologic procedures.
Clear preparation can make the experience more manageable. Patients should understand:
- Why HBOT is being recommended
- What symptoms it is intended to address
- That improvement may occur gradually
- How long each visit may take
- What sensations to expect during compression
- How treatment response will be evaluated
- What symptoms require urgent urologic care
The emotional burden of recurrent hematuria should not be underestimated. Seeing blood or clots in the urine can create persistent fear that the cancer has returned, even after testing identifies radiation injury as the likely cause. Compassionate care includes explaining the diagnosis clearly and maintaining appropriate cancer surveillance without dismissing the patient’s concern.
HBOT as Part of Coordinated Bladder-Preservation Care
The most effective management of radiation cystitis is multidisciplinary. Urologists address bleeding, obstruction, malignancy surveillance, and structural complications. Radiation oncologists help clarify the original treatment field and expected late effects. Hyperbaric clinicians evaluate whether increased tissue oxygenation may support recovery. Primary care and other specialists help manage anticoagulation, cardiopulmonary disease, diabetes, and treatment logistics.
HBOT occupies a distinctive position within this care pathway. Unlike therapies that cauterize, constrict, embolize, or chemically treat bleeding surfaces, HBOT is intended to improve the vascular environment of the irradiated bladder.
For an appropriately selected patient, that restorative approach may reduce hematuria, improve urinary symptoms, decrease reliance on repeated procedures, and support preservation of bladder function. The decision should be made after other causes of hematuria have been excluded and immediate bleeding risks have been controlled.
